Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 2076881

Cover Image

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 2076881

Radiotherapy Market by Technology, Procedure, Cancer, End User - Global Forecast to 2031

PUBLISHED:
PAGES: 328 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 4950
PDF (5-user License)
USD 6650
PDF (Corporate License)
USD 8150
PDF (Global License)
USD 10000

Add to Cart

Description

Table of Contents

List of Tables

The global radiotherapy market is expected to grow from USD 7.98 billion in 2026 to USD 10.68 billion by 2031, registering a CAGR of 6.0% during the forecast period.

Scope of the Report
Years Considered for the Study2026-2031
Base Year2025
Forecast Period2026-2031
Units ConsideredValue (USD billion)
SegmentsOffering, Technology, Application, Procedure, End User, and Region
Regions coveredNorth America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

The advancements in radiotherapy technology are expected to significantly boost market growth in the coming years. However, the high costs of radiotherapy products may hinder market expansion.

Radiotherapy Market - IMG1

"The external beam radiotherapy segment held the largest share of the market in 2025."

By technology, the radiotherapy market is categorized into external beam radiotherapy and internal beam radiotherapy/brachytherapy. During the forecast period, the external beam radiotherapy segment is expected to hold the largest market share. This is due to its ability to accurately target tumors while minimizing exposure to surrounding healthy tissue. The growth of this segment is driven by the increasing adoption of advanced procedures and a rising demand for precision medicine.

"The external beam radiotherapy procedures segment is expected to hold the largest share of the market in 2025."

By procedure, the radiotherapy market can be categorized into external beam radiotherapy and internal beam radiotherapy/brachytherapy procedures. The external beam radiotherapy procedures segment is expected to dominate the market during the forecast period. This is due to their accuracy, which allows for precise targeting of tumors while minimizing radiation exposure to healthy tissues. Additionally, external beam radiotherapy is commonly used to treat cancer. Innovations in image-guided and intensity-modulated radiotherapy systems are further driving the growth of this segment.

"The hospital segment is expected to hold the largest share of the market in 2025."

By end user, the radiotherapy market is categorized into hospitals and standalone radiotherapy centers. In the coming years, the hospitals segment is expected to capture the largest share of the global radiotherapy market. This growth can be attributed to several factors, including a high patient volume, the availability of advanced radiotherapy equipment, and the increasing demand for comprehensive cancer treatment facilities within hospitals. Additionally, the expansion of hospitals in developing countries, investments in healthcare infrastructure, and the availability of trained oncologists will further support the growth of this segment.

"The market in the APAC region is expected to register the highest growth rate during the forecast period."

The radiotherapy market is divided into five key regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America plays a significant role in the global radiotherapy market due to its established healthcare infrastructure, advanced radiotherapy equipment, favorable reimbursement policies, and the presence of key market players. However, the Asia Pacific region is expected to experience the highest growth rate during the forecast period. This growth is driven by the rising incidence of cancer, increased investment in healthcare, enhanced funding for oncology treatments, and advancements in healthcare infrastructure in countries such as China, India, and Japan, all of which have led to greater adoption of radiotherapy.

A breakdown of the primary participants referred to for this report is provided below:

  • By Company Type: Tier 1 (40%), Tier 2 (30%), and Tier 3 (30%)
  • By Designation: Directors (18%), C-level Executives (27%), and Other Designations (55%)
  • By Region: North America (50%), Europe (20%), Asia Pacific (10%), Latin America (10%), and the Middle East & Africa (10%)

The prominent players in the radiotherapy market are Siemens Healthineers GmbH (Germany), Elekta (Sweden), Accuray Incorporated (US), IBA WORLDWIDE (Belgium), ViewRay Technologies, Inc (US), Perspective Therapeutics, Inc. (US), Hitachi High Tech Corporation (Japan), Sumitomo Heavy Industries Ltd. (Japan), Carl Zeiss Meditec AG (Germany), and Koninklijke Philips N.V. (Netherlands), among others.

Research Coverage

This report studies the radiotherapy market based on offering, technology, application, procedure, end user, and region. It also covers the factors affecting market growth, analyzes the opportunities and challenges in the market, and provides details on the competitive landscape among market leaders. Furthermore, the report analyzes micromarkets by their individual growth trends and forecasts revenue for market segments across five main regions (and the countries within these regions).

Reasons to Buy the Report

The report will enable established firms, as well as entrants/smaller firms, to gauge the pulse of the market, which, in turn, will help them garner a larger market share. Firms purchasing the report could use one or a combination of the following strategies to strengthen their market presence.

This report provides insights into the following pointers:

  • Analysis of key drivers (advancements in radiotherapy treatment technology, growing patient population, increasing initiatives to promote radiotherapy awareness, and growing use of particle therapy for cancer treatment), restraints (high cost of advanced lab consumables and environmental sustainability concerns), opportunities (lack of adequate healthcare infrastructure, high capital cost of radiotherapy, and complexity of radiotherapy), and challenges (dearth of skilled personnel, difficulties in visualizing tumors during radiotherapy, and risk of Radiation Exposure) influencing the growth of the radiotherapy market.
  • Market Penetration: Comprehensive information on the product portfolios offered by the top players in the radiotherapy market.
  • Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product developments in the radiotherapy market.
  • Market Development: Comprehensive information on lucrative emerging regions.
  • Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the radiotherapy market.
  • Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.
Show more
Product Code: MD 1773

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
    • 1.3.2 INCLUSIONS & EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
    • 1.3.4 CURRENCY CONSIDERED
  • 1.4 STAKEHOLDERS
  • 1.5 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

  • 2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS
  • 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
  • 2.3 DISRUPTIVE TRENDS IN RADIOTHERAPY MARKET
  • 2.4 HIGH-GROWTH SEGMENTS
  • 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

  • 3.1 RADIOTHERAPY MARKET OVERVIEW
  • 3.2 RADIOTHERAPY MARKET, BY REGION
  • 3.3 NORTH AMERICA: RADIOTHERAPY MARKET, BY TECHNOLOGY AND COUNTRY
  • 3.4 GEOGRAPHIC SNAPSHOT OF RADIOTHERAPY MARKET

4 MARKET OVERVIEW

  • 4.1 INTRODUCTION
  • 4.2 MARKET DYNAMICS
    • 4.2.1 DRIVERS
      • 4.2.1.1 Advancements in radiotherapy treatment
      • 4.2.1.2 AI and automation in treatment planning
      • 4.2.1.3 Increasing government investments and awareness initiatives for cancer care
    • 4.2.2 RESTRAINTS
      • 4.2.2.1 High costs associated with radiotherapy systems such as proton therapy and advanced linear accelerators
      • 4.2.2.2 Limited access to advanced radiotherapy infrastructure and skilled workforce in low- and middle-income countries
      • 4.2.2.3 Shortage of skilled radiation oncologists, medical physicists, and trained technicians
    • 4.2.3 OPPORTUNITIES
      • 4.2.3.1 Emerging markets offer significant growth potential for radiotherapy technologies
      • 4.2.3.2 Integration of radiotherapy with immunotherapy and systemic therapies
      • 4.2.3.3 Growing adoption of outpatient radiotherapy and hypofractionated treatment regimens
    • 4.2.4 CHALLENGES
      • 4.2.4.1 Increasing cybersecurity and data protection challenges in digital radiotherapy ecosystems
      • 4.2.4.2 Patient safety concerns and radiation exposure risks
  • 4.3 UNMET NEEDS
  • 4.4 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

5 INDUSTRY TRENDS

  • 5.1 PORTER'S FIVE FORCES ANALYSIS
    • 5.1.1 INTENSITY OF COMPETITIVE RIVALRY
    • 5.1.2 BARGAINING POWER OF SUPPLIERS
    • 5.1.3 BARGAINING POWER OF BUYERS
    • 5.1.4 THREAT OF SUBSTITUTES
    • 5.1.5 THREAT OF NEW ENTRANTS
  • 5.2 MACROECONOMIC OUTLOOK
    • 5.2.1 GDP TRENDS AND FORECAST
    • 5.2.2 TRENDS IN GLOBAL RADIOTHERAPY INDUSTRY
  • 5.3 VALUE CHAIN ANALYSIS
    • 5.3.1 RESEARCH & DEVELOPMENT
    • 5.3.2 PROCUREMENT & MANUFACTURING
    • 5.3.3 MARKETING, SALES, AND DISTRIBUTION
  • 5.4 ECOSYSTEM ANALYSIS
  • 5.5 PRICING ANALYSIS
    • 5.5.1 AVERAGE SELLING PRICE TREND, BY REGION
  • 5.6 TRADE ANALYSIS
    • 5.6.1 IMPORT DATA (HS CODE 902214)
    • 5.6.2 EXPORT DATA (HS CODE 902214)
  • 5.7 KEY CONFERENCES & EVENTS, 2026-2027
  • 5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • 5.9 INVESTMENT & FUNDING SCENARIO
  • 5.10 CASE STUDY ANALYSIS
    • 5.10.1 SBRT'S ROLE IN MINIMIZING RADIATION RISK IN ELDERLY PATIENTS
    • 5.10.2 RADIOTHERAPY FOR BREAST CANCER IN PATIENTS WITH HEREDITARY COPROPORPHYRIA
    • 5.10.3 RADIATION THERAPY TREATMENT FOR TRANSITIONAL CELL CARCINOMA OF DISTAL URETHRA
  • 5.11 IMPACT OF 2025 US TARIFF - RADIOTHERAPY MARKET
    • 5.11.1 KEY TARIFF RATES
    • 5.11.2 PRICE IMPACT ANALYSIS
    • 5.11.3 IMPACT ON COUNTRIES/REGIONS
    • 5.11.4 IMPACT ON END-USE INDUSTRIES

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

  • 6.1 KEY TECHNOLOGIES
    • 6.1.1 MR-GUIDED ADAPTIVE RADIOTHERAPY
    • 6.1.2 ARTIFICIAL INTELLIGENCE-DRIVEN TREATMENT PLANNING
    • 6.1.3 PROTON AND PARTICLE THERAPY
  • 6.2 COMPLEMENTARY TECHNOLOGIES
    • 6.2.1 ADVANCED TREATMENT PLANNING SYSTEMS AND AI-ENABLED DECISION SUPPORT
    • 6.2.2 CLOUD-BASED AND REMOTE RADIOTHERAPY PLATFORMS
  • 6.3 PATENT ANALYSIS
    • 6.3.1 INNOVATIONS AND PATENT REGISTRATIONS
  • 6.4 FUTURE APPLICATIONS
  • 6.5 IMPACT OF AI/GEN AI ON RADIOTHERAPY MARKET
    • 6.5.1 TOP USE CASES AND MARKET POTENTIAL
    • 6.5.2 BEST PRACTICES FOLLOWED BY MANUFACTURERS IN RADIOTHERAPY MARKET
    • 6.5.3 CASE STUDIES RELATED TO AI IMPLEMENTATION IN RADIOTHERAPY MARKET
    • 6.5.4 INTERCONNECTED ECOSYSTEM AND IMPACT ON MARKET PLAYERS
    • 6.5.5 CLIENT'S READINESS TO ADOPT GENERATIVE AI IN RADIOTHERAPY MARKET
  • 6.6 SUCCESS STORIES AND REAL-WORLD APPLICATIONS

7 REGULATORY LANDSCAPE

  • 7.1 REGIONAL REGULATIONS AND COMPLIANCE
    • 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 7.1.2 INDUSTRY STANDARDS
      • 7.1.2.1 North America
        • 7.1.2.1.1 US
        • 7.1.2.1.2 Canada
      • 7.1.2.2 Europe
      • 7.1.2.3 Asia Pacific
        • 7.1.2.3.1 China
        • 7.1.2.3.2 Japan
        • 7.1.2.3.3 India

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

  • 8.1 DECISION-MAKING PROCESS
  • 8.2 KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS AND THEIR EVALUATION CRITERIA
    • 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 8.2.2 BUYING CRITERIA
  • 8.3 ADOPTION BARRIERS AND INTERNAL CHALLENGES
  • 8.4 UNMET NEEDS FROM END-USERS

9 RADIOTHERAPY MARKET, BY SYSTEM AND SOFTWARE & SERVICE

  • 9.1 INTRODUCTION
  • 9.2 SYSTEMS
    • 9.2.1 INCREASING ADOPTION OF AI-ENABLED AND IMAGE-GUIDED RADIOTHERAPY SYSTEMS TO DRIVE GROWTH
  • 9.3 SOFTWARE & SERVICES
    • 9.3.1 INCREASING ADOPTION OF INTEGRATED ONCOLOGY SOFTWARE PLATFORMS TO SUPPORT MARKET GROWTH

10 RADIOTHERAPY MARKET, BY APPLICATION

  • 10.1 INTRODUCTION
  • 10.2 EXTERNAL BEAM RADIOTHERAPY
    • 10.2.1 PROSTATE CANCER
      • 10.2.1.1 High incidence rate and efficiency of EBRT in prostate cancer treatment to support growth
    • 10.2.2 BREAST CANCER
      • 10.2.2.1 Therapeutic benefits of EBRT to drive market
    • 10.2.3 LUNG CANCER
      • 10.2.3.1 High prevalence of lung cancer and efficiency of EBRT to drive market
    • 10.2.4 HEAD & NECK CANCER
      • 10.2.4.1 Increasing preference for noninvasive treatment of head & neck cancers to drive market
    • 10.2.5 COLORECTAL CANCER
      • 10.2.5.1 High incidence of colorectal cancer to support market growth
    • 10.2.6 OTHER EBRT APPLICATIONS
  • 10.3 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY
    • 10.3.1 PROSTATE CANCER
      • 10.3.1.1 Precision of brachytherapy to drive market
    • 10.3.2 GYNECOLOGICAL CANCER
      • 10.3.2.1 Availability of alternatives to hinder adoption of brachytherapy
    • 10.3.3 BREAST CANCER
      • 10.3.3.1 Growing adoption of accelerated partial breast irradiation drives breast brachytherapy utilization
    • 10.3.4 CERVICAL CANCER
      • 10.3.4.1 MRI-guided adaptive brachytherapy and AI-enabled planning drive advances in cervical cancer treatment
    • 10.3.5 PENILE CANCER
      • 10.3.5.1 Increasing awareness of organ-preservation strategies to drive market
    • 10.3.6 OTHER IBRT APPLICATIONS

11 RADIOTHERAPY MARKET, BY PROCEDURE

  • 11.1 INTRODUCTION
  • 11.2 EXTERNAL BEAM RADIOTHERAPY
    • 11.2.1 IMAGE-GUIDED RADIOTHERAPY
      • 11.2.1.1 Growing adoption of real-time imaging and adaptive workflows to support market growth
    • 11.2.2 INTENSITY-MODULATED RADIOTHERAPY
      • 11.2.2.1 Growing adoption of hypofractionation and adaptive treatment planning to propel market
    • 11.2.3 PARTICLE THERAPY
      • 11.2.3.1 Advancements in treatment planning systems and expansion of proton therapy facilities to drive adoption
    • 11.2.4 3D CONFORMAL RADIOTHERAPY
      • 11.2.4.1 Continued utilization in resource-constrained settings to support adoption of 3D-CRT
    • 11.2.5 STEREOTACTIC RADIOTHERAPY
      • 11.2.5.1 Expanding clinical applications and hypofractionated treatment approaches to propel adoption
    • 11.2.6 OTHER EBRT PROCEDURES
  • 11.3 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY
    • 11.3.1 LDR BRACHYTHERAPY
      • 11.3.1.1 Low risk of radiation exposure to surrounding tissues to drive adoption
    • 11.3.2 HDR BRACHYTHERAPY
      • 11.3.2.1 Advancements in image-guided planning and dose optimization to drive growth
    • 11.3.3 PDR BRACHYTHERAPY
      • 11.3.3.1 Better radiation safety, easier prospective planning, and precise dose shaping to drive adoption

12 RADIOTHERAPY MARKET, BY TECHNOLOGY

  • 12.1 INTRODUCTION
  • 12.2 EXTERNAL BEAM RADIOTHERAPY
    • 12.2.1 LINACS
      • 12.2.1.1 Conventional LINACs
        • 12.2.1.1.1 Long treatment duration to limit adoption
      • 12.2.1.2 Stereotactic advanced electron/cobalt-60 LINACs
        • 12.2.1.2.1 CyberKnife
          • 12.2.1.2.1.1 Precise radiation delivery with robotic correction capabilities to drive market
        • 12.2.1.2.2 Gamma Knife
          • 12.2.1.2.2.1 Advancements in precision intracranial radiosurgery to drive adoption
        • 12.2.1.2.3 TomoTherapy
          • 12.2.1.2.3.1 Accurate targeting of tumors and minimization of exposure to surrounding healthy tissues to drive adoption
      • 12.2.1.3 MRI LINACs
        • 12.2.1.3.1 Real-time imaging advantage to propel growth
    • 12.2.2 PARTICLE THERAPY
      • 12.2.2.1 Cyclotrons
        • 12.2.2.1.1 Enhanced outcomes and other advantages to boost adoption
      • 12.2.2.2 Synchrotrons
        • 12.2.2.2.1 Increasing investments in synchrotron facilities to drive market
      • 12.2.2.3 Synchrocyclotrons
        • 12.2.2.3.1 Compact synchrocyclotron innovations support adoption despite infrastructure challenges
    • 12.2.3 CONVENTIONAL COBALT-60 TELETHERAPY
      • 12.2.3.1 Complex dose delivery planning and radiation exposure to limit market adoption
  • 12.3 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY
    • 12.3.1 SEEDS
      • 12.3.1.1 Adverse effects associated with brachytherapy seeds to limit adoption
    • 12.3.2 AFTERLOADERS
      • 12.3.2.1 Proper positioning and better control of isotopes in modern afterloaders to drive demand
    • 12.3.3 IORT SYSTEMS
      • 12.3.3.1 Growing clinical evidence supporting long-term efficacy to drive adoption
    • 12.3.4 APPLICATORS
      • 12.3.4.1 High risk of radiation exposure in manual applicators to limit growth

13 RADIOTHERAPY MARKET, BY END USER

  • 13.1 INTRODUCTION
  • 13.2 HOSPITALS
    • 13.2.1 INCREASING ADOPTION OF AI-ENABLED AND PRECISION RADIATION THERAPY SOLUTIONS TO DRIVE MARKET
  • 13.3 INDEPENDENT RADIOTHERAPY CENTERS
    • 13.3.1 EXPANSION OF RADIOTHERAPY INFRASTRUCTURE AND COMMUNITY-BASED CANCER CARE TO PROPEL MARKET

14 RADIOTHERAPY MARKET, BY REGION

  • 14.1 INTRODUCTION
  • 14.2 NORTH AMERICA
    • 14.2.1 US
      • 14.2.1.1 Favorable reimbursement scenario to drive growth
    • 14.2.2 CANADA
      • 14.2.2.1 Favorable initiatives from government and private organizations to boost market
  • 14.3 EUROPE
    • 14.3.1 GERMANY
      • 14.3.1.1 Availability of novel radiotherapy products to drive market
    • 14.3.2 FRANCE
      • 14.3.2.1 Presence of advanced healthcare systems to augment growth
    • 14.3.3 UK
      • 14.3.3.1 Growing adoption of advanced radiotherapy technologies and rising cancer burden to drive market
    • 14.3.4 SPAIN
      • 14.3.4.1 Adoption of advanced radiotherapy technologies to drive market
    • 14.3.5 ITALY
      • 14.3.5.1 Rising adoption of advanced radiotherapy technologies and strong research ecosystem to support market growth
    • 14.3.6 REST OF EUROPE
  • 14.4 ASIA PACIFIC
    • 14.4.1 JAPAN
      • 14.4.1.1 Favorable reimbursement policies to propel market
    • 14.4.2 CHINA
      • 14.4.2.1 Precision oncology investments to drive market
    • 14.4.3 INDIA
      • 14.4.3.1 Growing cancer burden, infrastructure investments, and advanced technology adoption to drive market
    • 14.4.4 SOUTH KOREA
      • 14.4.4.1 Rising investments in heavy-ion therapy infrastructure to propel market
    • 14.4.5 AUSTRALIA
      • 14.4.5.1 Growing cancer cases to fuel market
    • 14.4.6 REST OF ASIA PACIFIC
  • 14.5 LATIN AMERICA
    • 14.5.1 BRAZIL
      • 14.5.1.1 Increasing prevalence of cancer to fuel market
    • 14.5.2 MEXICO
      • 14.5.2.1 Expanding oncology infrastructure and precision radiotherapy adoption to drive growth
    • 14.5.3 REST OF LATIN AMERICA
  • 14.6 MIDDLE EAST & AFRICA
    • 14.6.1 GCC COUNTRIES
      • 14.6.1.1 Increasing investments in advanced oncology infrastructure to propel market
    • 14.6.2 REST OF MIDDLE EAST & AFRICA

15 COMPETITIVE LANDSCAPE

  • 15.1 INTRODUCTION
  • 15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 15.2.1 KEY PLAYER COMPETITIVE STRATEGIES IN RADIOTHERAPY MARKET, JANUARY 2022-MAY 2026
  • 15.3 REVENUE ANALYSIS, 2021-2025
  • 15.4 MARKET SHARE ANALYSIS, 2025
  • 15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
    • 15.5.1 STARS
    • 15.5.2 EMERGING LEADERS
    • 15.5.3 PERVASIVE PLAYERS
    • 15.5.4 PARTICIPANTS
    • 15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
      • 15.5.5.1 Company footprint
      • 15.5.5.2 Region footprint
      • 15.5.5.3 Technology footprint
      • 15.5.5.4 Application footprint
      • 15.5.5.5 End-user footprint
  • 15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
    • 15.6.1 PROGRESSIVE COMPANIES
    • 15.6.2 RESPONSIVE COMPANIES
    • 15.6.3 DYNAMIC COMPANIES
    • 15.6.4 STARTING BLOCKS
    • 15.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
      • 15.6.5.1 Detailed list of key startups/SMEs, 2025
      • 15.6.5.2 Competitive benchmarking of key startups/SMEs, 2025
  • 15.7 COMPANY VALUATION & FINANCIAL METRICS
  • 15.8 BRAND COMPARISON
  • 15.9 COMPETITIVE SCENARIO
    • 15.9.1 PRODUCT LAUNCHES & APPROVALS
    • 15.9.2 DEALS
    • 15.9.3 EXPANSIONS

16 COMPANY PROFILES

  • 16.1 KEY PLAYERS
    • 16.1.1 SIEMENS HEALTHINEERS AG
      • 16.1.1.1 Business overview
      • 16.1.1.2 Products/Solutions/Services offered
      • 16.1.1.3 Recent developments
        • 16.1.1.3.1 Product approvals
        • 16.1.1.3.2 Deals
      • 16.1.1.4 MnM view
        • 16.1.1.4.1 Key strengths
        • 16.1.1.4.2 Strategic choices
        • 16.1.1.4.3 Weaknesses & competitive threats
    • 16.1.2 ELEKTA
      • 16.1.2.1 Business overview
      • 16.1.2.2 Products/Solutions/Services offered
      • 16.1.2.3 Recent developments
        • 16.1.2.3.1 Product launches & approvals
        • 16.1.2.3.2 Deals
        • 16.1.2.3.3 Expansions
      • 16.1.2.4 MnM view
        • 16.1.2.4.1 Key strengths
        • 16.1.2.4.2 Strategic choices
        • 16.1.2.4.3 Weaknesses & competitive threats
    • 16.1.3 ACCURAY INCORPORATED
      • 16.1.3.1 Business overview
      • 16.1.3.2 Products/Solutions/Services offered
      • 16.1.3.3 Recent developments
        • 16.1.3.3.1 Product launches & approvals
        • 16.1.3.3.2 Deals
        • 16.1.3.3.3 Expansions
      • 16.1.3.4 MnM view
        • 16.1.3.4.1 Key strengths
        • 16.1.3.4.2 Strategic choices
        • 16.1.3.4.3 Weaknesses & competitive threats
    • 16.1.4 IBA WORLDWIDE
      • 16.1.4.1 Business overview
      • 16.1.4.2 Products/Solutions/Services offered
      • 16.1.4.3 Recent developments
        • 16.1.4.3.1 Products launches
        • 16.1.4.3.2 Deals
      • 16.1.4.4 MnM view
        • 16.1.4.4.1 Key strengths
        • 16.1.4.4.2 Strategic choices
        • 16.1.4.4.3 Weaknesses & competitive threats
    • 16.1.5 VIEWRAY SYSTEMS, INC.
      • 16.1.5.1 Business overview
      • 16.1.5.2 Products/Solutions/Services offered
      • 16.1.5.3 Recent developments
        • 16.1.5.3.1 Product approvals
        • 16.1.5.3.2 Deals
    • 16.1.6 GT MEDICAL TECHNOLOGIES, INC.
      • 16.1.6.1 Business overview
      • 16.1.6.2 Products/Solutions/Services offered
    • 16.1.7 HITACHI HIGH-TECH CORPORATION
      • 16.1.7.1 Business overview
      • 16.1.7.2 Products/Solutions/Services offered
      • 16.1.7.3 Recent developments
        • 16.1.7.3.1 Deals
    • 16.1.8 SUMITOMO HEAVY INDUSTRIES, LTD.
      • 16.1.8.1 Business overview
      • 16.1.8.2 Products/Solutions/Services offered
    • 16.1.9 ZEISS GROUP
      • 16.1.9.1 Business overview
      • 16.1.9.2 Products/solutions/services offered
      • 16.1.9.3 Recent developments
        • 16.1.9.3.1 Products launches
    • 16.1.10 MIM SOFTWARE INC.
      • 16.1.10.1 Business overview
      • 16.1.10.2 Products/Solutions/Services offered
      • 16.1.10.3 Recent developments
        • 16.1.10.3.1 Product launches & approvals
        • 16.1.10.3.2 Deals
    • 16.1.11 PANACEA MEDICAL TECHNOLOGIES PVT. LTD.
      • 16.1.11.1 Business overview
      • 16.1.11.2 Products/Solutions/Services offered
      • 16.1.11.3 Recent developments
        • 16.1.11.3.1 Product launches
        • 16.1.11.3.2 Deals
    • 16.1.12 PROVISION HEALTHCARE
      • 16.1.12.1 Business overview
      • 16.1.12.2 Products/Solutions/Services offered
    • 16.1.13 MEVION MEDICAL SYSTEMS
      • 16.1.13.1 Business overview
      • 16.1.13.2 Products/Solutions/Services offered
      • 16.1.13.3 Recent developments
        • 16.1.13.3.1 Product launches & approvals
        • 16.1.13.3.2 Deals
    • 16.1.14 KONINKLIJKE PHILIPS N.V.
      • 16.1.14.1 Business overview
      • 16.1.14.2 Products/Solutions/Services offered
      • 16.1.14.3 Recent developments
        • 16.1.14.3.1 Product launches
  • 16.2 OTHER PLAYERS
    • 16.2.1 SHINVA MEDICAL INSTRUMENT CO., LTD.
    • 16.2.2 BRAINLAB AG
    • 16.2.3 RAYSEARCH LABORATORIES
    • 16.2.4 INTRAOP MEDICAL, INC.
    • 16.2.5 OPTIVUS PROTON THERAPY, INC.
    • 16.2.6 BEBIG MEDICAL
    • 16.2.7 P-CURE
    • 16.2.8 THERAGENICS CORPORATION
    • 16.2.9 PROTOM INTERNATIONAL
    • 16.2.10 DOSISOFT SA
    • 16.2.11 ISOAID, LLC
    • 16.2.12 MAGNETTX ONCOLOGY SOLUTIONS LTD.

17 RESEARCH METHODOLOGY

  • 17.1 RESEARCH DATA
    • 17.1.1 SECONDARY DATA
      • 17.1.1.1 Objectives of secondary research
      • 17.1.1.2 List of secondary sources
    • 17.1.2 PRIMARY DATA
      • 17.1.2.1 Key data from primary sources
      • 17.1.2.2 Key industry insights
  • 17.2 MARKET ESTIMATION METHODOLOGY
    • 17.2.1 BOTTOM-UP APPROACH
    • 17.2.2 REVENUE MAPPING-BASED MARKET ESTIMATION
    • 17.2.3 USAGE-BASED MARKET ESTIMATION
    • 17.2.4 PRIMARY RESEARCH VALIDATION
    • 17.2.5 TOP-DOWN APPROACH
  • 17.3 DATA TRIANGULATION AND MARKET BREAKDOWN
  • 17.4 MARKET SHARE ASSESSMENT
  • 17.5 RESEARCH ASSUMPTIONS
  • 17.6 RESEARCH LIMITATIONS
  • 17.7 RISK ASSESSMENT
    • 17.7.1 RISK ASSESSMENT ANALYSIS

18 APPENDIX

  • 18.1 DISCUSSION GUIDE
  • 18.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 18.3 CUSTOMIZATION OPTIONS
  • 18.4 RELATED REPORTS
  • 18.5 AUTHOR DETAILS
Show more
Product Code: MD 1773

List of Tables

  • TABLE 1 RADIOTHERAPY MARKET: INCLUSION/EXCLUSION DETAILS
  • TABLE 2 DIFFERENT TYPES OF EXTERNAL BEAM RADIATION THERAPY (EBRT) TECHNIQUES AND ASSOCIATED ADVANTAGES AND DISADVANTAGES
  • TABLE 3 TREATMENT-RELATED EFFECTS AND TOXICITY CONCERNS
  • TABLE 4 RADIOTHERAPY MARKET: CURRENT UNMET NEEDS
  • TABLE 5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
  • TABLE 6 RADIOTHERAPY MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 7 AVERAGE SELLING PRICE TREND OF RADIOTHERAPY SYSTEMS, BY REGION, 2023-2025
  • TABLE 8 IMPORT DATA FOR HS CODE 902214-COMPLIANT PRODUCTS, BY COUNTRY, 2021-2025 (USD)
  • TABLE 9 EXPORT DATA FOR HS CODE 902214-COMPLIANT PRODUCTS, BY COUNTRY, 2021-2025 (USD)
  • TABLE 10 RADIOTHERAPY MARKET: KEY CONFERENCES & EVENTS, 2026-2027
  • TABLE 11 US-ADJUSTED RECIPROCAL TARIFF RATES IN MEDTECH INDUSTRY
  • TABLE 12 TARIFF-INDUCED PRICE INCREASES FOR HEALTHCARE PRODUCTS
  • TABLE 13 RADIOTHERAPY MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2020-2026
  • TABLE 14 KEY CLINICAL TRIALS EVALUATING ARTIFICIAL INTELLIGENCE IN RADIOTHERAPY
  • TABLE 15 KEY AI USE CASES AND MARKET POTENTIAL IN RADIOTHERAPY MARKET
  • TABLE 16 KEY CLINICAL CASE STUDIES OF ARTIFICIAL INTELLIGENCE APPLICATIONS IN RADIOTHERAPY
  • TABLE 17 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 18 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 19 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 20 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 21 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 22 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
  • TABLE 23 CLASS II PRESCRIBED EQUIPMENT CERTIFICATES
  • TABLE 24 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA
  • TABLE 25 INDIA: MEDICAL DEVICE CLASSIFICATION UNDER CDSCO
  • TABLE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF RADIOTHERAPY SYSTEMS
  • TABLE 27 KEY BUYING CRITERIA FOR RADIOTHERAPY SYSTEMS
  • TABLE 28 RADIOTHERAPY MARKET: CURRENT UNMET NEEDS
  • TABLE 29 RADIOTHERAPY MARKET, BY SYSTEM AND SOFTWARE & SERVICE 2024-2031 (USD MILLION)
  • TABLE 30 RADIOTHERAPY SYSTEMS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 31 RADIOTHERAPY SOFTWARE & SERVICES MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 32 RADIOTHERAPY MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 33 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 34 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 35 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET FOR PROSTATE CANCER, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 36 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET FOR BREAST CANCER, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 37 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET FOR LUNG CANCER, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 38 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET FOR HEAD & NECK CANCER, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 39 EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET FOR COLORECTAL CANCER, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 40 OTHER EBRT APPLICATIONS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 41 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 42 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 43 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET FOR PROSTATE CANCER, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 44 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET FOR GYNECOLOGICAL CANCER, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 45 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET FOR BREAST CANCER, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 46 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET FOR CERVICAL CANCER, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 47 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET FOR PENILE CANCER, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 48 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET FOR OTHER IBRT APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 49 RADIOTHERAPY MARKET, BY PROCEDURE, 2024-2031 (USD MILLION)
  • TABLE 50 EXTERNAL BEAM RADIOTHERAPY PROCEDURES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 51 EXTERNAL BEAM RADIOTHERAPY PROCEDURES MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 52 IMAGE-GUIDED RADIOTHERAPY MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 53 INTENSITY-MODULATED RADIOTHERAPY MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 54 PARTICLE THERAPY MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 55 3D CONFORMAL RADIOTHERAPY MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 56 STEREOTACTIC RADIOTHERAPY MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 57 OTHER EBRT PROCEDURES MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 58 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PROCEDURES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 59 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PROCEDURES MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 60 LDR BRACHYTHERAPY MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 61 HDR BRACHYTHERAPY MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 62 PDR BRACHYTHERAPY MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 63 RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 64 EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 65 EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 66 LINACS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 67 LINACS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 68 CONVENTIONAL LINACS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 69 STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 70 STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 71 CYBERKNIFE MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 72 GAMMA KNIFE MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 73 TOMOTHERAPY MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 74 MRI LINACS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 75 PARTICLE THERAPY MARKET, BY SYSTEM TYPE, 2024-2031 (USD MILLION)
  • TABLE 76 PARTICLE THERAPY MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 77 CYCLOTRONS THERAPY MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 78 SYNCHROTRONS THERAPY MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 79 SYNCHROCYCLOTRONS THERAPY MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 80 CONVENTIONAL COBALT-60 TELETHERAPY MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 81 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 82 INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 83 SEEDS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 84 AFTERLOADERS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 85 IORT SYSTEMS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 86 APPLICATORS MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 87 RADIOTHERAPY MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 88 RADIOTHERAPY MARKET FOR HOSPITALS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 89 RADIOTHERAPY MARKET FOR INDEPENDENT RADIOTHERAPY CENTERS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 90 RADIOTHERAPY MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 91 NORTH AMERICA: RADIOTHERAPY MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 92 NORTH AMERICA: RADIOTHERAPY MARKET, BY SYSTEM AND SOFTWARE & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 93 NORTH AMERICA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 94 NORTH AMERICA: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 95 NORTH AMERICA: LINACS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 96 NORTH AMERICA: STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 97 NORTH AMERICA: PARTICLE THERAPY MARKET, BY SYSTEM TYPE, 2024-2031 (USD MILLION)
  • TABLE 98 NORTH AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 99 NORTH AMERICA: EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 100 NORTH AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 101 NORTH AMERICA: EXTERNAL BEAM RADIOTHERAPY PROCEDURES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 102 NORTH AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PROCEDURES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 103 NORTH AMERICA: RADIOTHERAPY MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 104 US: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 105 US: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 106 US: LINACS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 107 US: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 108 CANADA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 109 CANADA: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 110 CANADA: LINACS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 111 CANADA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 112 EUROPE: RADIOTHERAPY MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 113 EUROPE: RADIOTHERAPY MARKET, BY SYSTEM AND SOFTWARE & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 114 EUROPE: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 115 EUROPE: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 116 EUROPE: LINACS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 117 EUROPE: STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 118 EUROPE: PARTICLE THERAPY MARKET, BY SYSTEM TYPE, 2024-2031 (USD MILLION)
  • TABLE 119 EUROPE: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 120 EUROPE: EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 121 EUROPE: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 122 EUROPE: EXTERNAL BEAM RADIOTHERAPY PROCEDURES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 123 EUROPE: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PROCEDURES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 124 EUROPE: RADIOTHERAPY MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 125 GERMANY: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 126 GERMANY: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 127 GERMANY: LINACS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 128 GERMANY: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 129 FRANCE: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 130 FRANCE: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 131 FRANCE: LINACS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 132 FRANCE: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 133 UK: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 134 UK: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 135 UK: LINACS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 136 UK: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 137 SPAIN: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 138 SPAIN: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 139 SPAIN: LINACS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 140 SPAIN: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 141 ITALY: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 142 ITALY: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 143 ITALY: LINACS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 144 ITALY: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 145 REST OF EUROPE: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 146 REST OF EUROPE: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 147 REST OF EUROPE: LINACS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 148 REST OF EUROPE: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 149 ASIA PACIFIC: RADIOTHERAPY MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 150 ASIA PACIFIC: RADIOTHERAPY MARKET, BY SYSTEM AND SOFTWARE & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 151 ASIA PACIFIC: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 152 ASIA PACIFIC: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 153 ASIA PACIFIC: LINACS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 154 ASIA PACIFIC: STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 155 ASIA PACIFIC: PARTICLE THERAPY MARKET, BY SYSTEM TYPE, 2024-2031 (USD MILLION)
  • TABLE 156 ASIA PACIFIC: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 157 ASIA PACIFIC: EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 158 ASIA PACIFIC: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 159 ASIA PACIFIC: EXTERNAL BEAM RADIOTHERAPY PROCEDURES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 160 ASIA PACIFIC: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PROCEDURES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 161 ASIA PACIFIC: RADIOTHERAPY MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 162 JAPAN: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 163 JAPAN: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 164 JAPAN: LINACS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 165 JAPAN: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 166 CHINA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 167 CHINA: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 168 CHINA: LINACS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 169 CHINA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 170 INDIA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 171 INDIA: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 172 INDIA: LINACS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 173 INDIA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 174 SOUTH KOREA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 175 SOUTH KOREA: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 176 SOUTH KOREA: LINACS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 177 SOUTH KOREA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 178 AUSTRALIA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 179 AUSTRALIA: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 180 AUSTRALIA: LINACS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 181 AUSTRALIA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 182 REST OF ASIA PACIFIC: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 183 REST OF ASIA PACIFIC: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 184 REST OF ASIA PACIFIC: LINACS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 185 REST OF ASIA PACIFIC: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 186 LATIN AMERICA: RADIOTHERAPY MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 187 LATIN AMERICA: RADIOTHERAPY MARKET, BY SYSTEM AND SOFTWARE & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 188 LATIN AMERICA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 189 LATIN AMERICA: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 190 LATIN AMERICA: LINACS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 191 LATIN AMERICA: STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 192 LATIN AMERICA: PARTICLE THERAPY MARKET, BY SYSTEM TYPE, 2024-2031 (USD MILLION)
  • TABLE 193 LATIN AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 194 LATIN AMERICA: EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 195 LATIN AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 196 LATIN AMERICA: EXTERNAL BEAM RADIOTHERAPY PROCEDURES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 197 LATIN AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PROCEDURES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 198 LATIN AMERICA: RADIOTHERAPY MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 199 BRAZIL: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 200 BRAZIL: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 201 BRAZIL: LINACS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 202 BRAZIL: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 203 MEXICO: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 204 MEXICO: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 205 MEXICO: LINACS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 206 MEXICO: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 207 REST OF LATIN AMERICA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 208 REST OF LATIN AMERICA: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 209 REST OF LATIN AMERICA: LINACS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 210 REST OF LATIN AMERICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 211 MIDDLE EAST & AFRICA: RADIOTHERAPY MARKET, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 212 MIDDLE EAST & AFRICA: RADIOTHERAPY MARKET, BY SYSTEM AND SOFTWARE & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 213 MIDDLE EAST & AFRICA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 214 MIDDLE EAST & AFRICA: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 215 MIDDLE EAST & AFRICA: LINACS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 216 MIDDLE EAST & AFRICA: STEREOTACTIC ADVANCED ELECTRON/COBALT-60 LINACS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 217 MIDDLE EAST & AFRICA: PARTICLE THERAPY MARKET, BY SYSTEM TYPE, 2024-2031 (USD MILLION)
  • TABLE 218 MIDDLE EAST & AFRICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 219 MIDDLE EAST & AFRICA: EXTERNAL BEAM RADIOTHERAPY APPLICATIONS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 220 MIDDLE EAST & AFRICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY APPLICATIONS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 221 MIDDLE EAST & AFRICA: EXTERNAL BEAM RADIOTHERAPY PROCEDURES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 222 MIDDLE EAST & AFRICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY PROCEDURES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 223 MIDDLE EAST & AFRICA: RADIOTHERAPY MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 224 GCC COUNTRIES: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 225 GCC COUNTRIES: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 226 GCC COUNTRIES: LINACS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 227 GCC COUNTRIES: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 228 REST OF MIDDLE EAST & AFRICA: RADIOTHERAPY MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 229 REST OF MIDDLE EAST & AFRICA: EXTERNAL BEAM RADIOTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 230 REST OF MIDDLE EAST & AFRICA: LINACS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 231 REST OF MIDDLE EAST & AFRICA: INTERNAL BEAM RADIOTHERAPY/BRACHYTHERAPY TECHNOLOGIES MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 232 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN RADIOTHERAPY MARKET, JANUARY 2022-MAY 2026
  • TABLE 233 RADIOTHERAPY MARKET: DEGREE OF COMPETITION
  • TABLE 234 RADIOTHERAPY MARKET: REGION FOOTPRINT
  • TABLE 235 RADIOTHERAPY MARKET: TECHNOLOGY FOOTPRINT
  • TABLE 236 RADIOTHERAPY MARKET: APPLICATION FOOTPRINT
  • TABLE 237 RADIOTHERAPY MARKET: END-USER FOOTPRINT
  • TABLE 238 RADIOTHERAPY MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS
  • TABLE 239 RADIOTHERAPY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
  • TABLE 240 RADIOTHERAPY MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022-MAY 2026
  • TABLE 241 RADIOTHERAPY MARKET: DEALS, JANUARY 2022-MAY 2026
  • TABLE 242 RADIOTHERAPY MARKET: EXPANSIONS, JANUARY 2022-MAY 2026
  • TABLE 243 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
  • TABLE 244 SIEMENS HEALTHINEERS AG: PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • TABLE 245 SIEMENS HEALTHINEERS AG: PRODUCT APPROVALS, JANUARY 2022-MAY 2026
  • TABLE 246 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2022-MAY 2026
  • TABLE 247 ELEKTA: COMPANY OVERVIEW
  • TABLE 248 ELEKTA: PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • TABLE 249 ELEKTA: PRODUCTS LAUNCHES & APPROVALS, JANUARY 2022-MAY 2026
  • TABLE 250 ELEKTA: DEALS, JANUARY 2022-MAY 2026
  • TABLE 251 ELEKTA: EXPANSIONS, JANUARY 2022-MAY 2026
  • TABLE 252 ACCURAY INCORPORATED: COMPANY OVERVIEW
  • TABLE 253 ACCURAY INCORPORATED: PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • TABLE 254 ACCURAY INCORPORATED: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022-MAY 2026
  • TABLE 255 ACCURAY INCORPORATED: DEALS, JANUARY 2022-MAY 2026
  • TABLE 256 ACCURAY INCORPORATED: EXPANSIONS, JANUARY 2022-MAY 2026
  • TABLE 257 IBA WORLDWIDE: COMPANY OVERVIEW
  • TABLE 258 IBA WORLDWIDE: PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • TABLE 259 IBA WORLDWIDE: PRODUCT LAUNCHES, JANUARY 2022-MAY 2026
  • TABLE 260 IBA WORLDWIDE: DEALS, JANUARY 2022-MAY 2026
  • TABLE 261 VIEWRAY SYSTEMS, INC.: COMPANY OVERVIEW
  • TABLE 262 VIEWRAY SYSTEMS, INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • TABLE 263 VIEWRAY SYSTEMS, INC.: PRODUCT APPROVALS, JANUARY 2022-MAY 2026
  • TABLE 264 VIEWRAY SYSTEMS, INC.: DEALS, JANUARY 2022-MAY 2026
  • TABLE 265 GT MEDICAL TECHNOLOGIES, INC.: COMPANY OVERVIEW
  • TABLE 266 GT MEDICAL TECHNOLOGIES, INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • TABLE 267 HITACHI HIGH-TECH CORPORATION: COMPANY OVERVIEW
  • TABLE 268 HITACHI HIGH-TECH CORPORATION: PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • TABLE 269 HITACHI HIGH-TECH CORPORATION: DEALS, JANUARY 2022-MAY 2026
  • TABLE 270 SUMITOMO HEAVY INDUSTRIES, LTD.: COMPANY OVERVIEW
  • TABLE 271 SUMITOMO HEAVY INDUSTRIES, LTD.: PRODUCTS/SOLUTIONS/ SERVICES OFFERED
  • TABLE 272 ZEISS GROUP : COMPANY OVERVIEW
  • TABLE 273 ZEISS GROUP: PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • TABLE 274 ZEISS GROUP: PRODUCT LAUNCHES, JANUARY 2022-MAY 2026
  • TABLE 275 MIM SOFTWARE INC.: COMPANY OVERVIEW
  • TABLE 276 MIM SOFTWARE INC.: PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • TABLE 277 MIM SOFTWARE INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022-MAY 2026
  • TABLE 278 MIM SOFTWARE INC.: DEALS, JANUARY 2022-MAY 2026
  • TABLE 279 PANACEA MEDICAL TECHNOLOGIES PVT. LTD.: COMPANY OVERVIEW
  • TABLE 280 PANACEA MEDICAL TECHNOLOGIES PVT. LTD.: PRODUCTS/SOLUTIONS/ SERVICES OFFERED
  • TABLE 281 PANACEA MEDICAL TECHNOLOGIES PVT. LTD.: PRODUCT LAUNCHES , JANUARY 2022-MAY 2026
  • TABLE 282 PANACEA MEDICAL TECHNOLOGIES PVT. LTD.: DEALS, JANUARY 2022-MAY 2026
  • TABLE 283 PROVISION HEALTHCARE: COMPANY OVERVIEW
  • TABLE 284 PROVISION HEALTHCARE: PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • TABLE 285 MEVION MEDICAL SYSTEMS: COMPANY OVERVIEW
  • TABLE 286 MEVION MEDICAL SYSTEMS: PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • TABLE 287 MEVION MEDICAL SYSTEMS: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022-MAY 2026
  • TABLE 288 MEVION MEDICAL SYSTEMS: DEALS, JANUARY 2022-MAY 2026
  • TABLE 289 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW
  • TABLE 290 KONINKLIJKE PHILIPS N.V.: PRODUCTS/SOLUTIONS/SERVICES OFFERED
  • TABLE 291 KONINKLIJKE PHILIPS N.V.: PRODUCT LAUNCHES, JANUARY 2022-MAY 2026
  • TABLE 292 SHINVA MEDICAL INSTRUMENT CO., LTD.: COMPANY OVERVIEW
  • TABLE 293 BRAINLAB AG: COMPANY OVERVIEW
  • TABLE 294 RAYSEARCH LABORATORIES: COMPANY OVERVIEW
  • TABLE 295 INTRAOP MEDICAL, INC.: COMPANY OVERVIEW
  • TABLE 296 OPTIVUS PROTON THERAPY, INC.: COMPANY OVERVIEW
  • TABLE 297 BEBIG MEDICAL: COMPANY OVERVIEW
  • TABLE 298 P-CURE: COMPANY OVERVIEW
  • TABLE 299 THERAGENICS CORPORATION: COMPANY OVERVIEW
  • TABLE 300 PROTOM INTERNATIONAL: COMPANY OVERVIEW
  • TABLE 301 DOSISOFT SA: COMPANY OVERVIEW
  • TABLE 302 ISOAID, LLC: COMPANY OVERVIEW
  • TABLE 303 MAGNETTX ONCOLOGY SOLUTIONS LTD.: COMPANY OVERVIEW
  • TABLE 304 RADIOTHERAPY MARKET: RESEARCH ASSUMPTIONS

List of Figures

  • FIGURE 1 RADIOTHERAPY MARKET SEGMENTATION AND REGIONAL SCOPE
  • FIGURE 2 DURATION COVERED
  • FIGURE 3 MARKET SCENARIO
  • FIGURE 4 GLOBAL RADIOTHERAPY MARKET, 2024-2031
  • FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN RADIOTHERAPY MARKET, 2022-2026
  • FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF RADIOTHERAPY MARKET
  • FIGURE 7 HIGH-GROWTH SEGMENTS IN RADIOTHERAPY MARKET, 2026-2031
  • FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN RADIOTHERAPY MARKET DURING FORECAST PERIOD
  • FIGURE 9 ADVANCEMENTS IN AI AND ADAPTIVE RADIOTHERAPY ENHANCE TREATMENT PRECISION
  • FIGURE 10 NORTH AMERICA TO ACCOUNT FOR LARGEST MARKET SHARE DURING STUDY PERIOD
  • FIGURE 11 EXTERNAL BEAM RADIATION THERAPY SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN MARKET IN 2025
  • FIGURE 12 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • FIGURE 13 RADIOTHERAPY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 14 RADIOTHERAPY MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 15 RADIOTHERAPY MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 16 RADIOTHERAPY MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 17 AVERAGE SELLING PRICE TREND OF RADIOTHERAPY SYSTEMS, BY REGION, 2023-2025 (USD)
  • FIGURE 18 IMPORT DATA FOR HS CODE 902214-COMPLIANT PRODUCTS, BY COUNTRY, 2021-2025
  • FIGURE 19 EXPORT DATA FOR HS CODE 902214-COMPLIANT PRODUCTS, BY COUNTRY, 2021-2025
  • FIGURE 20 RADIOTHERAPY MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
  • FIGURE 21 RADIOTHERAPY MARKET: INVESTMENT & FUNDING SCENARIO, 2019-2023
  • FIGURE 22 RADIOTHERAPY MARKET: NUMBER OF INVESTOR DEALS, BY KEY PLAYER, 2019-2023
  • FIGURE 23 VALUE OF INVESTOR DEALS IN RADIOTHERAPY MARKET, BY KEY PLAYER, 2019-2023
  • FIGURE 24 PATENT ANALYSIS FOR RADIOTHERAPY MARKET, JANUARY 2016-DECEMBER 2025
  • FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF RADIOTHERAPY SYSTEMS
  • FIGURE 26 KEY BUYING CRITERIA FOR RADIOTHERAPY SYSTEMS
  • FIGURE 27 NORTH AMERICA: RADIOTHERAPY MARKET SNAPSHOT
  • FIGURE 28 ASIA PACIFIC: RADIOTHERAPY MARKET SNAPSHOT
  • FIGURE 29 REVENUE ANALYSIS OF KEY PLAYERS IN RADIOTHERAPY MARKET, 2021-2025
  • FIGURE 30 MARKET SHARE ANALYSIS OF KEY PLAYERS IN RADIOTHERAPY MARKET, 2025
  • FIGURE 31 RADIOTHERAPY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
  • FIGURE 32 RADIOTHERAPY MARKET: COMPANY FOOTPRINT
  • FIGURE 33 RADIOTHERAPY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
  • FIGURE 34 EV/EBITDA OF KEY VENDORS
  • FIGURE 35 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 36 RADIOTHERAPY MARKET: BRAND COMPARATIVE ANALYSIS
  • FIGURE 37 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT
  • FIGURE 38 ELEKTA: COMPANY SNAPSHOT
  • FIGURE 39 ACCURAY INCORPORATED: COMPANY SNAPSHOT
  • FIGURE 40 IBA WORLDWIDE: COMPANY SNAPSHOT
  • FIGURE 41 HITACHI HIGH-TECH CORPORATION: COMPANY SNAPSHOT
  • FIGURE 42 SUMITOMO HEAVY INDUSTRIES, LTD.: COMPANY SNAPSHOT
  • FIGURE 43 ZEISS GROUP: COMPANY SNAPSHOT
  • FIGURE 44 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT
  • FIGURE 45 RESEARCH DESIGN
  • FIGURE 46 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 47 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 48 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
  • FIGURE 49 RADIOTHERAPY MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ESTIMATION)
  • FIGURE 50 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2025)
  • FIGURE 51 RADIOTHERAPY MARKET: MARKET SIZE ESTIMATION METHODOLOGY
  • FIGURE 52 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
  • FIGURE 53 DATA TRIANGULATION METHODOLOGY
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!